82/100 · Critical
Manufactured by Church & Dwight Co., Inc.
Dimenhydrinate Adverse Events: High Serious Reaction Rate
53,959 FDA adverse event reports analyzed
Last updated: 2026-05-12
DIMENHYDRINATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Church & Dwight Co., Inc.. Based on analysis of 53,959 FDA adverse event reports, DIMENHYDRINATE has a safety score of 82 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for DIMENHYDRINATE include NAUSEA, FATIGUE, OFF LABEL USE, HEADACHE, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DIMENHYDRINATE.
Dimenhydrinate has a safety concern score of 82 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 53,959 adverse event reports for this medication, which is primarily manufactured by Church & Dwight Co., Inc..
The most commonly reported adverse events include Nausea, Fatigue, Off Label Use. Of classified reports, 94.9% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Nausea, fatigue, and dizziness are the most frequently reported adverse events.
A significant number of serious reactions, including pneumonia and chest discomfort, are noted. The reaction diversity is high, with over 100 distinct reactions reported.
Patients taking Dimenhydrinate should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Dimenhydrinate may interact with other medications, potentially affecting its efficacy or causing adverse reactions. Consult a healthcare provider before combining with other drugs. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Dimenhydrinate received a safety concern score of 82/100 (high concern). This is based on a 94.9% serious event ratio across 10,197 classified reports. The score accounts for 53,959 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 6,057, Male: 2,944, Unknown: 8. The most frequently reported age groups are age 61 (276 reports), age 41 (221 reports), age 65 (205 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 10,197 classified reports for DIMENHYDRINATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Dimenhydrinate may interact with other medications, potentially affecting its efficacy or causing adverse reactions. Consult a healthcare provider before combining with other drugs.
If you are taking Dimenhydrinate, here are important things to know. The most commonly reported side effects include nausea, fatigue, off label use, headache, vomiting. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Always follow the prescribed dosage and duration of use as directed by a healthcare provider. Be aware of potential serious reactions and seek medical attention if they occur. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor Dimenhydrinate for safety. Consumers should report any adverse events to the FDA's MedWatch program.
The FDA has received approximately 53,959 adverse event reports associated with Dimenhydrinate. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Dimenhydrinate include Nausea, Fatigue, Off Label Use, Headache, Vomiting. By volume, the top reported reactions are: Nausea (2,379 reports), Fatigue (1,768 reports), Off Label Use (1,730 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Dimenhydrinate.
Out of 10,197 classified reports, 9,680 (94.9%) were classified as serious and 517 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Dimenhydrinate break down by patient sex as follows: Female: 6,057, Male: 2,944, Unknown: 8. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Dimenhydrinate adverse events are: age 61: 276 reports, age 41: 221 reports, age 65: 205 reports, age 53: 200 reports, age 66: 184 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Dimenhydrinate adverse event reports is Church & Dwight Co., Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Dimenhydrinate include: Malaise, Diarrhoea, Dizziness, Pain, Drug Ineffective. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Dimenhydrinate to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Dimenhydrinate has a safety concern score of 82 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Nausea, fatigue, and dizziness are the most frequently reported adverse events.
Key safety signals identified in Dimenhydrinate's adverse event data include: Pneumonia and chest discomfort are key serious safety signals.. Drug ineffectiveness and pyrexia are common, indicating potential efficacy issues.. Aplastic anemia and angina pectoris are rare but serious safety signals.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Dimenhydrinate may interact with other medications, potentially affecting its efficacy or causing adverse reactions. Consult a healthcare provider before combining with other drugs. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Dimenhydrinate.
Always follow the prescribed dosage and duration of use as directed by a healthcare provider. Be aware of potential serious reactions and seek medical attention if they occur.
Dimenhydrinate has 53,959 adverse event reports on file with the FDA. A significant number of serious reactions, including pneumonia and chest discomfort, are noted. The volume of reports for Dimenhydrinate reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor Dimenhydrinate for safety. Consumers should report any adverse events to the FDA's MedWatch program. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
The following drugs share commonly reported adverse reactions with DIMENHYDRINATE:
Drugs related to DIMENHYDRINATE based on therapeutic use, drug class, or shared indications: